FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 14, 2009--
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has received
a subpoena from the Office of the Inspector General of the Department of
Health and Human Services requesting documents regarding the
development, marketing and sales of Ranexa® (ranolazine).
Ranexa is approved for the treatment of chronic angina and was developed
and originally commercialized by CV Therapeutics, a company that Gilead
acquired in April 2009.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com
or call the Gilead Public Affairs Department at 1-800-GILEAD-5
(1-800-445-3235).
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Amy
Flood, 650-522-5643 (Media)
